Advaxis (ADXS) Stock Price Down 0%

Advaxis, Inc. (NASDAQ:ADXS) shares traded down 0% during mid-day trading on Friday . The company traded as low as $1.80 and last traded at $1.80. 8,429,000 shares changed hands during trading, an increase of 671% from the average session volume of 1,093,070 shares. The stock had previously closed at $1.80.

A number of research analysts recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $23.00 target price on shares of Advaxis in a research report on Wednesday, November 8th. Cantor Fitzgerald set a $19.00 target price on shares of Advaxis and gave the company a “buy” rating in a research report on Friday, December 22nd. Finally, ValuEngine upgraded shares of Advaxis from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.

The firm has a market capitalization of $82.44, a PE ratio of -0.82 and a beta of 0.70.

Advaxis (NASDAQ:ADXS) last issued its quarterly earnings data on Wednesday, December 20th. The biotechnology company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.02). The firm had revenue of $1.76 million during the quarter, compared to analyst estimates of $3.05 million. Advaxis had a negative return on equity of 114.00% and a negative net margin of 776.63%. equities analysts anticipate that Advaxis, Inc. will post -2.36 EPS for the current year.

Several institutional investors have recently modified their holdings of the business. Schwab Charles Investment Management Inc. raised its position in shares of Advaxis by 0.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 129,321 shares of the biotechnology company’s stock worth $840,000 after acquiring an additional 817 shares during the period. Wells Fargo & Company MN raised its position in shares of Advaxis by 2.6% in the second quarter. Wells Fargo & Company MN now owns 44,813 shares of the biotechnology company’s stock worth $290,000 after acquiring an additional 1,144 shares during the period. TIAA CREF Investment Management LLC raised its position in shares of Advaxis by 2.4% in the second quarter. TIAA CREF Investment Management LLC now owns 98,164 shares of the biotechnology company’s stock worth $637,000 after acquiring an additional 2,329 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of Advaxis by 10.4% in the second quarter. The Manufacturers Life Insurance Company now owns 31,431 shares of the biotechnology company’s stock worth $204,000 after acquiring an additional 2,969 shares during the period. Finally, Voya Investment Management LLC raised its position in shares of Advaxis by 20.3% in the second quarter. Voya Investment Management LLC now owns 17,612 shares of the biotechnology company’s stock worth $114,000 after acquiring an additional 2,975 shares during the period. Institutional investors and hedge funds own 37.39% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.thelincolnianonline.com/2018/02/25/advaxis-adxs-stock-price-down-0.html.

Advaxis Company Profile

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply